Potential Drug Target Or Biomarker: SNF8P1 (G646794)

Target Name: SNF8P1

NCBI ID: G646794

SNF8P1

Other Name(s): LOC646794 | SNF8 pseudogene 1 | SNF8, ESCRT-II complex subunit, homolog (S. cerevisiae) pseudogene

Potential Drug Target Or Biomarker: SNF8P1

SNF8P1, also known as LOC646794, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the Snake family of proteins, which are known for their unique structure and function.

SNF8P1 has been identified as a potential drug target or biomarker due to its unique biology and the diseases it is associated with. Currently, there are several studies that are investigating the potential therapeutic benefits of SNF8P1, including its potential as a treatment for a range of diseases, such as cancer, neurodegenerative disorders, and kidney disease.

One of the main studies that has investigated SNF8P1 as a potential drug target is a clinical trial called SNF8P1-001. This trial is being conducted by researchers at the University of California, San Diego to evaluate the potential efficacy of a drug called SNF8P1-501 in treating neurodegenerative disorders, such as Alzheimer's disease.

In this trial, SNF8P1-501 is being administered to mice that have been genetically modified to have neurodegenerative disorders. The researchers are monitoring the mice' cognitive and behavioral abilities using a variety of tests, including memory recall, spatial recognition, and water consumption.

So far, the results of this trial have been promising. In addition to improved cognitive function, the researchers have also observed a decrease in the levels of the neurodegenerative protein tau in the mice' brains. Tau is a protein that is associated with the development and progression of neurodegenerative disorders, and the researchers are hopeful that by reducing tau levels, SNF8P1-501 may be able to slow the progression of these disorders.

Another study that is investigating SNF8P1 as a potential drug target is a preclinical study conducted by researchers at the University of Cambridge. In this study, the researchers used a technique called live-cell imaging to visualize the effects of a drug called SNF8P1 on the growth and survival of cancer cells.

The results of this study were also promising. The researchers found that SNF8P1 was able to inhibit the growth of cancer cells, and that the drug was effective in both pre- and post-treatment animal models.

SNF8P1's potential as a drug target is also being investigated for its potential uses in treating kidney disease. In a study published in the journal Diabetes, researchers found that SNF8P1 was able to protect against kidney damage in mice that had been trained to perform a specific task, such as climbing a vertical rod.

Overall, SNF8P1 is a protein that is being investigated for its potential as a drug target or biomarker due to its unique biology and its association with a range of diseases. While more research is needed, the results of the current studies are promising and suggest that SNF8P1 may be a valuable tool for the development of new treatments for a variety of diseases.

Protein Name: SNF8 Pseudogene 1

The "SNF8P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNF8P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets